药物基因组指导的高血压个性化治疗:一个多中心随机试验
Mingzhong Yu1,2,3,4,5, Min Pan1,2,3,4,5, Bangbang Huang1,2,3,4,5
1Department of Geriatrics, the First Affiliated Hospital of Fujian Medical University.
Journal of hypertension
|February 26, 2026
概括
药物基因组学引导的个性化药物显著改善了血压控制,并减少了高血压患者的药物需求. 这种精准医学方法可以改善高血压的管理,而不会增加不良事件.
科学领域:
- 心脏病学 心脏病学
- 药物基因组学 药物基因组学
- 精准医学是一门精准的医学.
背景情况:
- 失控的高血压对医疗保健构成了重大挑战.
- 药物基因组学为个性化高血压管理提供了潜力.
研究的目的:
- 评估药物基因组学引导的个性化药物是否能改善血压控制,并优化高血压患者的药物治疗与标准护理相比.
主要方法:
- 一个多中心,单盲,随机对照试验,涉及776名高血压门诊患者.
- 患者被分配到一个个性化药物组 (以7种药物遗传多态为指导) 或对照组.
- 评估结果包括血压控制,药物使用和8周治疗后的不良事件.
主要成果:
- 个性化药物组的血压控制率显着更高,特别是在女性患者中.
- 在个性化组中,需要使用的抗高血压药物较少.
- 两组之间没有观察到不良事件的显著差异;CYP2C9*3变异与不受控制的血压有关.
结论:
- 以药物遗传学为指导的个性化药物治疗方案有效地改善了血压控制和药物优化.
- 这种精确治疗方法可以提高高血压的管理,而不会增加安全问题.
- 药物基因组学有望将抗高血压治疗量身定制为个人遗传特征.
关键词:
这是ACEI.其他有害反应 (ADRs)这是一个ARB ARB.抗胰岛素II受体阻断剂 抗胰岛素II受体阻断剂抗氨酸转化酶抑制剂 抗氨酸转化酶抑制剂这就是为什么B.P.B.B.B.中央银行 (CCB) 的中央银行 (CCB) 的中央银行 (CCB) 的中央银行 (CCB).这是一个MAP MAP.这就是为什么PPPPPPPPPPPPPP不良反应是不良反应.血压 血压 血压 血压血压控制 控制血压 控制血压通道阻塞剂 通道阻塞剂血压的变化 血压的变化基因多态的多态化这种高血压,高血压.平均动脉压力是指动脉的压力.个性化的药物治疗.药物基因组学 药物基因组学脉冲压力 脉冲压力 脉冲压力的 ΔBPBP 值.相关概念视频
Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
63
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
63
Pharmacogenetics and Pharmacogenomics: Overview
74
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
74
Pharmacogenetics of Drug Metabolism: Overview
68
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
68
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
Hypertension IV: Drug Therapy and Lifestyle Modifications
790
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
790

